Désirée A M van Oorschot (Desirée Van Oorschot, Desiree Van Oorschot, Desirée A M van Oorschot, Désirée van Oorschot)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 13

Top Topics

Randomized Controlled Trial

Artificial Intelligence

Top Venues

Human vaccines & immunotherapeutics

Infectious diseases and therapy

Expert review of anti-infective therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Ru Han, Jorge A Gomez, Bruna de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics (2023)
Ru Han, Jorge A Gomez, Bruna de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Ru Han, Jorge A Gomez, Bruna de Veras, Thatiana de Jesus Pereira Pinto, Adriana Guzmán-Holst, Javier Nieto Guevara, Désirée A M van Oorschot
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be? Human vaccines & immunotherapeutics 19 (1) (2023)
Enrique Chacon-Cruz, Erika Zoe Lopatynsky-Reyes, Gloria Huerta-Garcia, Maria Yolanda Cervantes-Apolinar, Adriana Guzmán-Holst, Désirée A M van Oorschot
Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico. Human vaccines & immunotherapeutics (2022)
Alen Marijam, Ekaterina Safonova, Mikhail Scherbakov, Evgeniy Shpeer, Désirée A M van Oorschot, Alla Rudakova, Vladimir Tatochenko, Nikolay Briko
Cost effectiveness and budget impact of universal varicella vaccination in Russia. Human vaccines & immunotherapeutics 18 (5) (2022)
Désirée A M van Oorschot, Hilde Vroling, Eveline M Bunge, John D Diaz-Decaro, Desmond Curran, Barbara P Yawn
A systematic literature review of herpes zoster incidence worldwide. Human vaccines & immunotherapeutics 17 (6) (2021)
Desmond Curran, Andrea Callegaro, Kyle Fahrbach, Binod Neupane, Hilde Vroling, Désirée A M van Oorschot, Barbara P Yawn
Meta-Regression of Herpes Zoster Incidence Worldwide. Infectious diseases and therapy (2021)
Desmond Curran, Désirée A M van Oorschot, Sean Matthews, Johannes Hain, Ahmed Ehab Salem, Magdalena Schwarz
Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Human vaccines & immunotherapeutics 17 (12) (2021)
Dapeng Yin, Désirée A M van Oorschot, Ning Jiang, Alen Marijam, Debasish Saha, Zhenhua Wu, Haiwen Tang, John D Diaz-Decaro, Phil Watson, Xueqiong Xie, Yifan Ren, Yu He, Yang Feng
A systematic literature review to assess the burden of herpes zoster disease in China. Expert review of anti-infective therapy 19 (2) (2020)
Désirée A M van Oorschot, Manjit Hunjan, Benjamin Bracke, Stéphane Lorenc, Desmond Curran, Helen Starkie-Camejo
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ open 9 (5) (2019)